Skip to content

Celldex Therapeutics CLDX Cash Flow Statement

FY'25FY'24FY'23FY'22
-$258.76M-63.9%-$157.86M-11.6%-$141.43M-25.9%-$112.33M-59.3%
$3.38M+6.4%$3.18M+5.6%$3.01M+3.9%$2.9M-5.6%
$36.22M+5.8%$34.24M+43.3%$23.89M+53.0%$15.61M+74.4%
-$210.95M-33.7%-$157.78M-47.1%-$107.29M-3.4%-$103.73M-70.3%
$2.71M+41.4%$1.92M+5.6%$1.82M-0.5%$1.83M+46.4%
$209.07M-$105.78M-218%$89.94M+142%
$2.39M-99.5%$441.45M+102%$218.46M+5,260%$4.08M-98.5%
$5.39M
-$213.66M-33.8%-$159.7M-46.4%-$109.11M-3.4%-$105.56M-69.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Celldex Therapeutics generate?
Celldex Therapeutics (CLDX) generated -$222.2M in operating cash flow over the trailing twelve months.
What is Celldex Therapeutics's free cash flow?
After $4.1M of capital expenditures, Celldex Therapeutics's free cash flow was -$226.2M over the trailing twelve months, down 30.5% year over year.
Where does Celldex Therapeutics's cash flow data come from?
Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.